For decades, a diagnosis of wet age-related macular degeneration (wet AMD) carried a grim prognosis. That changed with the arrival of anti-VEGF injections — treatments given into the eye that block the chemical signal driving abnormal blood vessel growth. For the first time, most patients could keep, and often improve, their vision. The same class of treatment reshaped the outlook for polypoidal choroidal vasculopathy (PCV), a related condition that is particularly common in Asian eyes.

Injections work — but they are not perfect. Some eyes never dry completely. Others do well at first but need injections so frequently that keeping up becomes a burden for patients and families. This is the problem the newest treatments are designed to solve: not to replace what works, but to make control steadier and less demanding. This article explains, without jargon or brand names, what has changed and what it means if wet AMD or PCV affects you or someone you care for.

"The question I hear most often is, 'Will I need injections for the rest of my life?' The honest answer used to be, 'Probably, and often.' Today, for many patients, it is, 'Likely fewer than before' — and that changes lives."

— Dr. Wong Chee Wai

Wet AMD and PCV: A Quick Refresher

Both conditions share a common thread: abnormal, fragile blood vessels grow beneath the retina and leak fluid or blood into the delicate central retina (the macula), the part responsible for sharp, detailed vision. As fluid accumulates and, in time, scar tissue forms, central vision becomes blurred, distorted, or blocked.

Wet AMD is an advanced form of age-related macular degeneration in which these new vessels grow in response to ageing changes at the back of the eye. PCV is a distinct variant in which the abnormal vessels form small, balloon-like dilations — "polyps" — often accompanied by a branching vascular network. PCV frequently requires a special dye test called indocyanine green (ICG) angiography to diagnose accurately, because it can be missed on standard imaging. Telling the two apart matters, because the ideal treatment plan differs.

How Injection Treatment Works

The established foundation of treatment is a group of medicines known as anti-VEGF agents. VEGF (vascular endothelial growth factor) is the primary molecular signal that tells abnormal vessels to grow and leak. Anti-VEGF injections neutralise that signal, allowing the retina to dry and stabilise. Treatment usually begins with a series of monthly injections, after which the interval is gradually extended for as long as the eye remains stable.

For most patients this approach preserves vision that would otherwise have been lost. But VEGF is only part of the story — and that is precisely why some eyes need something more.

Why Some Eyes Need More Than Anti-VEGF Alone

Wet AMD and PCV are not driven by a single molecule. Alongside VEGF, other pathways contribute to leaky, unstable vessels — including one governed by a protein called angiopoietin-2 (Ang-2), which destabilises blood vessels and amplifies inflammation. When treatment targets VEGF alone, these other drivers can keep the disease simmering. In practice, that shows up as retinal fluid that never fully clears, or as a need for injections every few weeks indefinitely.

Two goals emerged from this understanding: dry the retina more completely, and make each injection last longer so patients need fewer of them.

What Is New in Treatment

Recent advances broadly fall into three categories. None of them is a cure, and the right choice is always individual — but together they represent a meaningful step forward.

Targeting more than one pathway

Dual-pathway injections

A newer class of injection blocks both VEGF and the angiopoietin-2 pathway at the same time. By calming vessel instability from two directions, these agents aim for a drier retina and more durable control — which for many patients means longer gaps between injections.

Making treatment last longer

Longer-acting & higher-dose options

Other advances focus on extending durability — through higher-concentration formulations or slow-release approaches — so that stable eyes can be maintained with fewer visits. Fewer injections reduces the practical and emotional burden of treatment without compromising control.

Tailoring PCV treatment

Combination therapy for PCV

For PCV specifically, injections may be combined with photodynamic therapy (PDT) — a light-activated treatment that closes off polypoidal lesions. Combining approaches can achieve lesion regression that injections alone may not, and is chosen based on ICG imaging findings.

A Closer Look at PCV

PCV deserves special mention because it is so relevant to patients of Asian descent, in whom it accounts for a substantial share of what might otherwise be labelled "wet AMD." Because PCV behaves differently — with a tendency to recur and, occasionally, to cause sudden large bleeds under the retina — it benefits from precise diagnosis and a treatment plan built around its particular biology. Modern management aims not just to reduce fluid but to regress the underlying polyps, and to identify early which eyes are likely to stay quiet after treatment.

What matters most: treat early, monitor closely

Whatever the specific medicine, two principles hold true. First, early treatment protects vision — sight lost to bleeding or scarring is hard to recover, while timely treatment preserves what remains. Second, monitoring guides everything: a quick, painless OCT scan at each visit shows whether the retina is dry and tells your ophthalmologist when the interval between injections can safely be extended.

What This Means For You

If you are living with wet AMD or PCV, the headline is genuinely hopeful: the tools to control these conditions are better than they have ever been, and for many patients the treatment burden is falling. The best regimen for your eye depends on your diagnosis, how your retina has responded so far, and your own preferences and circumstances — which is a conversation to have with your ophthalmologist rather than a decision that can be made from an article.

What has not changed is the value of acting early and keeping to your monitoring schedule. If you notice new distortion of straight lines, a blur or dark patch in your central vision, or a sudden drop in sight, treat it as urgent and seek assessment within days.

Frequently Asked Questions

Will I need injections forever?

Not necessarily, but many patients do need ongoing treatment. Wet AMD and PCV are chronic conditions; injections control the disease rather than cure it. The encouraging change is that newer, longer-acting treatments let many patients stretch the interval between injections while keeping the retina dry. Your ophthalmologist extends the gap as far as your eye safely allows.

What is the difference between wet AMD and PCV?

Both involve abnormal blood vessels beneath the retina that can leak and bleed. PCV is a distinct variant, more common in Asian patients, in which the abnormal vessels form polyp-like dilations. It often requires ICG angiography to diagnose and may be treated with injections, photodynamic therapy, or a combination. Distinguishing the two matters because it changes the plan.

Are the newer injections better than the older ones?

Newer agents are designed to control disease with less frequent injections and, in some eyes, to dry the retina more completely. That does not mean older treatments stopped working — they remain effective and are the right choice for many patients. The best option depends on your specific disease and response, and is a decision to make with your ophthalmologist.

How soon should wet AMD or PCV be treated?

As soon as possible. Vision lost to bleeding or scarring is often difficult to recover, whereas early treatment preserves the vision you still have. New distortion, a blurred or dark central patch, or a sudden drop in vision should be assessed urgently — within days, not weeks.